Mukka Proteins

Has Mukka Proteins declared dividend?

No Dividend History Available

Who are the peers of the Mukka Proteins?

Mukka Proteins' peers include Godavari Bioref., HMA Agro Inds., Aayush Wellness, and others, with Aayush Wellness showing excellent management risk and the highest 1-year return at 1374.42%, while Mukka Proteins has a 1-year return of -45.04%. Growth is good for Mukka Proteins and a few others, but its capital structure is below average compared to peers.

Peers: The peers of Mukka Proteins are Godavari Bioref., HMA Agro Inds., Andrew Yule & Co, Aayush Wellness, Jindal Photo, Vadilal Enterp., SKM Egg Prod., Foods & Inns, and Apex Frozen Food.<BR><BR>Quality Snapshot: Excellent management risk is observed at Aayush Wellness and the rest have Average management risk. Growth is Good at Mukka Proteins, Vadilal Enterp., SKM Egg Prod., and Aayush Wellness, while the rest show Below Average or Average growth. Capital Structure is Good at Aayush Wellness, Vadilal Enterp., and SKM Egg Prod., while Below Average capital structure is found at Mukka Proteins, Andrew Yule & Co, HMA Agro Inds., Jindal Photo, Foods & Inns, and the rest.<BR><BR>Return Snapshot: Aayush Wellness has the highest 1-year return at 1374.42%, while HMA Agro Inds. has the lowest at -42.55%, with Mukka Proteins' 1-year return of -45.04% being lower than both. Additionally, Jindal Photo and Foods & Inns are among the peers with negative six-month returns.

What does Mukka Proteins do?

Mukka Proteins Ltd is a micro-cap FMCG company that specializes in protein products, with recent net sales of ₹3,816 Cr and a net profit of ₹136 Cr as of March 2025. The company has a market cap of ₹897 Cr and key financial metrics include a P/E ratio of 19.00 and a debt-equity ratio of 0.93.

Overview:<BR>Mukka Proteins Ltd operates in the FMCG industry and is categorized as a micro-cap company.<BR><BR>History:<BR>Mukka Proteins Limited was originally incorporated as "Mukka Sea Food Industries" in Karnataka on March 13, 2003. It was converted from a partnership firm to a private company on November 04, 2010. The latest quarterly results report net sales and profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 3,816 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 136 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: INR 897 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 19.00 <BR>Industry P/E: 20 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.93 <BR>Return on Equity: 10.47% <BR>Price to Book: 2.03 <BR><BR>Contact Details:<BR>No Company Details Available <BR>Registrar Address: Not available.

Who are the top shareholders of the Mukka Proteins?

The top shareholders of Mukka Proteins include Mohammed Haris K, who holds 30.23%, followed by 7 Foreign Institutional Investors with 2.63%, and Neomile Growth Fund - Series I with 1.98%. Individual investors own 19.85%, with no pledged promoter holdings or mutual fund investments.

The top shareholders of Mukka Proteins include the promoters, who hold the majority of the shares. The promoter with the highest holding is Mohammed Haris K, who owns 30.23% of the company. Additionally, there are 7 Foreign Institutional Investors (FIIs) holding a combined 2.63% of the shares. The highest public shareholder is Neomile Growth Fund - Series I, which holds 1.98%. Individual investors collectively own 19.85% of the company. There are no pledged promoter holdings, and no mutual funds are currently invested in Mukka Proteins.

How big is Mukka Proteins?

As of 24th July, Mukka Proteins Ltd has a market capitalization of 875.00 Cr, with recent net sales of 1006.42 Cr and a net profit of 46.16 Cr. The company reported shareholder's funds of 396.09 Cr and total assets of 940.79 Cr for the annual period ending March 2024.

As of 24th July, Mukka Proteins Ltd has a market capitalization of 875.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Mukka Proteins reported Net Sales of 1006.42 Cr and a Net Profit of 46.16 Cr.<BR><BR>For the latest annual period ending March 2024, the company had Shareholder's Funds of 396.09 Cr and Total Assets amounting to 940.79 Cr.

How has been the historical performance of Mukka Proteins?

Mukka Proteins has shown fluctuating performance, with net sales declining to 1,006.42 Cr in March 2025 from 1,379.83 Cr in March 2024, alongside decreases in profitability, while total assets increased to 1,076.32 Cr. The company faced a challenging year marked by negative cash flow and reduced profits.

Answer:<BR>The historical performance of Mukka Proteins shows a fluctuating trend in net sales and profitability over the years, with a notable decline in the most recent fiscal year.<BR><BR>Breakdown:<BR>Mukka Proteins reported net sales of 1,006.42 Cr for the year ending March 2025, a decrease from 1,379.83 Cr in March 2024 and 1,177.12 Cr in March 2023, but an increase from 770.50 Cr in March 2022. Total operating income mirrored this trend, reaching 1,006.42 Cr in March 2025. The company's total expenditure, excluding depreciation, was 911.53 Cr in March 2025, down from 1,274.36 Cr in March 2024, while operating profit (PBDIT) was 110.01 Cr, showing a decline from 121.79 Cr in the previous year. Profit before tax also decreased to 59.20 Cr in March 2025 from 84.35 Cr in March 2024. Consequently, profit after tax fell to 47.03 Cr from 71.20 Cr. The company's total assets increased to 1,076.32 Cr in March 2025, up from 940.79 Cr in March 2024, and total liabilities also rose to 1,076.32 Cr from 940.79 Cr. Cash flow from operating activities remained negative at -111.00 Cr in March 2025, although cash and cash equivalents decreased to 3.00 Cr from 94.00 Cr in March 2024. Overall, Mukka Proteins experienced a challenging year with declining sales and profits, despite an increase in total assets and liabilities.

Is Mukka Proteins overvalued or undervalued?

As of November 14, 2025, Mukka Proteins is considered very attractive and undervalued with a PE ratio of 16.74 and an EV to EBITDA of 12.74, outperforming peers like Avanti Feeds and Apex Frozen Foods, and has delivered an 8.16% return compared to the Sensex's 1.62%.

As of 14 November 2025, Mukka Proteins has moved from an attractive to a very attractive valuation grade. The company is currently considered undervalued, supported by a PE ratio of 16.74, an EV to EBITDA ratio of 12.74, and a PEG ratio of 0.00, indicating strong potential for growth relative to its price. <BR><BR>In comparison with peers, Avanti Feeds has a PE ratio of 16.54 and an EV to EBITDA of 10.04, while Apex Frozen Foods shows a significantly higher PE ratio of 43.53, suggesting that Mukka Proteins is positioned favorably within its industry. Additionally, the company's recent stock performance has outpaced the Sensex over the past week, with an 8.16% return compared to the Sensex's 1.62%, reinforcing the notion of its undervaluation.

Is Mukka Proteins technically bullish or bearish?

As of December 3, 2025, Mukka Proteins is in a mildly bearish trend, supported by bearish daily moving averages and Bollinger Bands, despite some mixed signals from the MACD and RSI across different timeframes.

As of 3 December 2025, the technical trend for Mukka Proteins has changed from sideways to mildly bearish. The current stance is bearish, with key indicators supporting this view. The daily moving averages are bearish, and both the weekly and monthly Bollinger Bands are also bearish. Although the weekly MACD and KST are mildly bullish, the overall sentiment is tempered by the bearish signals from the moving averages and Bollinger Bands. The RSI shows no signal on the weekly timeframe, while it is bullish on the monthly, indicating mixed signals across different timeframes. Overall, the bearish trend is currently stronger, reflecting the recent price decline from the previous close.

When is the next results date for Mukka Proteins Ltd?

The next results date for Mukka Proteins Ltd is 12 February 2026.

The next results date for Mukka Proteins Ltd is scheduled for 12 February 2026.

Are Mukka Proteins Ltd latest results good or bad?

Mukka Proteins Ltd's latest results show impressive revenue growth with a consolidated net profit of ₹23.75 crore, but significant concerns arise from a sharp decline in operating margins to 7.16% and high debt levels, indicating potential challenges in sustaining profitability. Investors should be cautious about the company's operational difficulties despite the strong sales figures.

Mukka Proteins Ltd's latest results present a mixed picture. On one hand, the company achieved a remarkable consolidated net profit of ₹23.75 crore in Q3 FY26, which is a substantial increase of 303.91% compared to the previous quarter. Additionally, net sales soared to ₹653.50 crore, reflecting a 167.19% increase quarter-on-quarter and a strong 115.57% year-on-year growth.<BR><BR>However, the positive revenue growth comes with significant concerns regarding profitability. The operating margin has contracted sharply to 7.16%, down from 13.96% in the same quarter last year, indicating challenges in maintaining profitability despite the impressive sales figures. This margin compression raises questions about the company's pricing power and cost management in a competitive seafood processing industry.<BR><BR>Furthermore, while the profit after tax margin improved sequentially, it still decreased year-on-year, highlighting ongoing challenges in converting revenue growth into sustainable profits. The company's high debt levels and the substantial interest costs also add to the financial strain.<BR><BR>In summary, while Mukka Proteins has demonstrated explosive revenue growth, the significant margin compression and financial leverage issues suggest that the overall results are not entirely positive. Investors should be cautious and consider the sustainability of this growth in the context of the company's operational challenges.

Should I buy, sell or hold Mukka Proteins Ltd?

Why is Mukka Proteins Ltd falling/rising?

As of 03-Apr, Mukka Proteins Ltd's stock price is rising due to positive quarterly results and short-term gains, but the long-term outlook is concerning with a -38.04% return over the past year and weak fundamental strength.

As of 03-Apr, Mukka Proteins Ltd's stock price is rising, currently at 20.47, reflecting a change of 0.28 or 1.39% increase. This upward movement can be attributed to several factors. Notably, the stock has outperformed its sector by 2.07% today and has experienced consecutive gains over the last two days, accumulating a total return of 11.31% during this period. Additionally, the company recently declared positive quarterly results, reporting net sales growth of 137.6% and a profit after tax growth of 101.1% compared to the previous four-quarter average. This strong performance has contributed to a more attractive valuation, as the stock is trading at a discount relative to its peers' historical valuations.<BR><BR>However, it is important to note that despite the recent rise, the stock has faced significant challenges over the longer term. It has generated a return of -38.04% over the past year and has shown weak long-term fundamental strength, with a -4.98% compound annual growth rate in operating profits over the last five years. Additionally, the company has a high debt to EBITDA ratio, indicating low ability to service debt, which could weigh on investor sentiment moving forward. Furthermore, there has been a decline in institutional investor participation, with a decrease in their stake by -1.5% over the previous quarter. <BR><BR>In summary, while Mukka Proteins Ltd is currently experiencing a rise in stock price due to recent positive financial results and short-term gains, the long-term outlook remains concerning due to historical performance and fundamental weaknesses.

Why is Mukka Proteins Ltd falling/rising?

As of 04-Apr, Mukka Proteins Ltd's stock price is rising due to recent positive financial results and short-term performance gains, despite concerns about long-term fundamentals and declining investor participation.

As of 04-Apr, Mukka Proteins Ltd's stock price is rising, currently at 20.47, reflecting a change of 0.28 or 1.39% increase. This upward movement can be attributed to several factors. Notably, the stock has outperformed its sector by 2.07% today and has experienced consecutive gains over the last two days, accumulating a total return of 11.31% during this period. <BR><BR>Additionally, the company recently declared positive financial results for December 2025, marking a significant turnaround after seven consecutive quarters of negative performance. Key metrics such as Profit Before Tax (PBT) and Profit After Tax (PAT) have shown substantial growth, with PBT increasing by 157.1% and PAT by 101.1% compared to the previous four-quarter average. Furthermore, net sales reached their highest at Rs 653.50 crore, indicating strong operational performance.<BR><BR>Despite these positive developments, it is important to note that the stock is still trading below its longer-term moving averages, which may indicate underlying weaknesses. Moreover, there has been a decline in investor participation, with delivery volume falling by 43.31% against the five-day average. This suggests that while the stock is currently rising, there are concerns regarding its long-term fundamental strength, as evidenced by a negative CAGR growth in operating profits over the past five years and a high Debt to EBITDA ratio.<BR><BR>In summary, Mukka Proteins Ltd is experiencing a rise in its stock price due to recent positive financial results and short-term performance gains, despite ongoing concerns about its long-term fundamentals and declining investor participation.

Why is Mukka Proteins Ltd falling/rising?

As of 05-Apr, Mukka Proteins Ltd's stock price is rising to 20.47, reflecting a 1.39% increase. This short-term gain follows positive financial results, including a significant profit increase, despite a challenging long-term performance and declining institutional interest.

As of 05-Apr, Mukka Proteins Ltd's stock price is rising, currently at 20.47, with a change of 0.28 (1.39%) upwards. This increase can be attributed to several factors. Notably, the stock has been gaining for the last two days, achieving a total return of 11.31% during this period. Additionally, it has outperformed its sector by 2.07% today.<BR><BR>The company recently declared positive results for December 2025, breaking a streak of seven consecutive negative quarters. Key financial metrics show significant growth, with profit before tax increasing by 157.1% compared to the previous four-quarter average, and profit after tax rising by 101.1%. Furthermore, net sales reached their highest at Rs 653.50 crore, indicating strong operational performance.<BR><BR>Despite these positive developments, the stock has faced challenges in the longer term, including a decline of 38.04% over the past year and a weak long-term fundamental strength, evidenced by a -4.98% CAGR growth in operating profits over the last five years. Additionally, there has been a decrease in institutional investor participation, which may impact future performance. However, the current upward movement in stock price reflects a short-term positive sentiment driven by recent financial results and a temporary rebound in trading activity.

Which are the latest news on Mukka Proteins?